Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medical Developments International Limited ( (AU:MVP) ) has provided an announcement.
Medical Developments International reported group revenue of $10.7 million for the December 2025 quarter and $21.6 million for the first half of FY26, with the half-year result up $1.6 million on the prior period, driven by a $2.3 million increase in Penthrox revenue and stronger volumes in Australia and Europe. The company generated $1.1 million in operating cash in Q2 and achieved positive operating cashflow of $0.3 million for the half, ending the period with $16.9 million in cash, while its respiratory segment faced softer US demand despite price increases to offset higher tariff-related costs. Operationally, Penthrox posted 26% volume growth in the Australian hospital segment, benefited from expanded PBS Prescriber Bag eligibility to nurse practitioners, and recorded 10% in‑market volume growth in Europe, where paediatric label approvals are progressing. Management signalled plans to invest further in growth initiatives and partner support to embed Penthrox as a standard of care and leverage the new paediatric indication, cautioning that these investments and distribution changes in France and Switzerland are expected to weigh on FY26 underlying EBIT but are aimed at delivering stronger long‑term financial performance.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
More about Medical Developments International Limited
Medical Developments International Limited (ASX: MVP) is an Australian medical technology company focused on pain management and respiratory products. Its flagship product is Penthrox, an inhaled, non-opioid analgesic used in emergency and procedural pain settings, with growing adoption in Australian hospitals and expanding markets in Europe and other international regions. The company also operates a respiratory segment with products sold into the US and other markets.
Average Trading Volume: 87,002
Technical Sentiment Signal: Sell
Current Market Cap: A$54.64M
Find detailed analytics on MVP stock on TipRanks’ Stock Analysis page.